In a retrospective study of Medicare patients with cancer, patients treated with Voraxaze® had all of the following benefits compared to nonglucarpidase patients treated with dialysis (dialysis+) and nonglucarpidase patients with or without dialysis treatment (dialysis+/-), respectively1*:
*Utilizing Medicare inpatient claims data between 2010 and 2017, investigators compared outcomes and healthcare resource utilization between patients treated with Voraxaze® (n=30) and patients not treated with Voraxaze® (n=701), all of whom had experienced AKI secondary to inpatient chemotherapy.
Mean length of stay (LOS) among patients treated with Voraxaze® and the non-Voraxaze® groups1
Rates of mortality among patients treated with Voraxaze® and the non-Voraxaze® groups1
Voraxaze® patients treated within 3 days of admission (n=18) had shorter ICU and hospital LOS compared to Voraxaze® patients treated after 3 days (n=12).
Not every patient requires Voraxaze®, but experts have assembled recommendations to help guide treatment.
Explore the guidelines for the use and stocking of Voraxaze® so that you’re prepared in an emergency.